À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : Á¦Ç° À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Implantable Drug Delivery Devices Market Size, Share, Trends and Forecast by Product Type, Technology, Application, End User, and Region, 2025-2033
»óǰÄÚµå
:
1675780
¸®¼Ä¡»ç
:
IMARC Group
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 144 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 152¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö 275¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ̸ç, 2025-2033³â CAGRÀº 6.47%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 40.7% ÀÌ»óÀÇ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, À̽ÄÇü ÀåÄ¡ÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü µîÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
À̽ÄÇü ¾à¹°Àü´Þ ±â±â´Â ü³»¿¡ À̽ÄÇÏ¿© Àå±â°£¿¡ °ÉÃÄ ¾à¹°À» Áö¼ÓÀûÀ¸·Î ¹æÃâÇÒ ¼ö ÀÖ´Â ÀåÄ¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ ±¸Á¶¿¡´Â ÀúÀå¼Ò ¶Ç´Â ¾à¹° ÇÔÀ¯ ±¸È¹, ¹æÃâ ¸ÞÄ¿´ÏÁò, ¾à¹° ¼öÁØ ¶Ç´Â »ý¸®Àû ÆÄ¶ó¹ÌÅ͸¦ ¸ð´ÏÅ͸µÇÏ°í ½Ç½Ã°£À¸·Î Çǵå¹éÀ» Á¦°øÇÏ´Â ¼¾¼ µî ¸î °¡Áö ÁÖ¿ä ±¸¼º¿ä¼Ò°¡ Æ÷ÇԵ˴ϴÙ. À̽ÄÇü ¾à¹°Àü´Þ ±â±â´Â Ç÷·ù ³» ¾à¹° ³óµµ¸¦ ÀÏÁ¤ÇÏ°Ô À¯ÁöÇÏ°í °æ±¸ ¾à¹°¿¡ ¼ö¹ÝµÇ´Â ÇÇÅ©¿Í °ñÂ¥±â¸¦ ÇÇÇÒ ¼ö ÀÖ´Â µî ±âÁ¸ ¾à¹° Åõ¿© ¹æ½Ä¿¡ ºñÇØ ¸¹Àº ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. À̸¦ ÅëÇØ ÃÖÀûÀÇ Ä¡·á ¼öÁØÀ» º¸ÀåÇϰí ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ÀåÄ¡´Â ƯÁ¤ °£°ÝÀ¸·Î ¾à¹°À» ¹æÃâÇϵµ·Ï ÇÁ·Î±×·¡¹ÖÇÒ ¼ö Àֱ⠶§¹®¿¡ ºó¹øÇÑ Åõ¿©ÀÇ Çʿ伺À» ÁÙ¿© ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, À̽ÄÇü ¾à¹°Àü´Þ ±â±â´Â ±¹¼ÒÀû ¾à¹°Àü´ÞÀ» °¡´ÉÇÏ°Ô ÇÏ¿© Àü½Å ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇϰí Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ´Ù¾çÇÑ À¯ÇüÀÇ À̽ÄÇü ¾à¹°Àü´Þ ±â±â°¡ ÀÌ¿ë °¡´ÉÇϸç, ±× Áß¿¡´Â ¸ðÅÍ ±¸µ¿ ¸ÞÄ¿´ÏÁòÀ» ÀÌ¿ëÇÏ¿© Àú¼öÁö¿¡¼ ¾à¹°À» Á¦¾îµÈ ¼Óµµ·Î ¹Ð¾î³»´Â À̽ÄÇü ÆßÇÁµµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.
À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀå µ¿Çâ:
¼¼°è À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀåÀº ÁÖ·Î ¾Ï, ´ç´¢º´, ½ÉÇ÷°üÁúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡ µî ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ë·É Àα¸ÀÇ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ýºÐÇØ¼º ¹× ÇÁ·Î±×·¥ °¡´ÉÇÑ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß°ú °°Àº À̽ÄÇü ÀåÄ¡ÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü°ú Àå±âÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ÀÇ·á ºñ¿ë Àý°¨¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí À¯¸®ÇÑ »óȯ Á¤Ã¥ÀÇ °¡¿ë¼ºÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó °¢±¹ Á¤ºÎ´Â ÷´Ü ÀÇ·á ±â¼úÀ» ÃËÁøÇϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Âü½ÅÇϰí Çõ½ÅÀûÀÎ À̽ÄÇü ¾à¹°Àü´Þ ±â±â¸¦ µµÀÔÇϱâ À§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ÀÇ È°¼ºÈµµ ½ÃÀå °³Ã´ÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ À̽ÄÇü ¾à¹°Àü´Þ ±â±âÀÇ ÀåÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû ¾à¹°Àü´Þ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀåÀÇ ½ÃÀå ±Ô¸ð´Â?
- À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀåÀÇ ÇâÈÄ Àü¸ÁÀº?
- À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
- À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀå Á¡À¯À²ÀÌ °¡Àå ³ôÀº Áö¿ªÀº ¾îµðÀΰ¡?
- ¼¼°è À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀåÀÇ ÁÖ¿ä ¾÷ü´Â?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ À̽ÄÇü ¾à¹°Àü´Þ ±â±â ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°
- À̽ÄÇü ¾à¹° ¿ëÃâ ½ºÅÙÆ®
- À̽ÄÇü ÇÇÀÓ ¾à¹°Àü´Þ ±â±â
- À̽ÄÇü ¾È³» ¾à¹°Àü´Þ ±â±â
- À̽ÄÇü ±ÙÁ¢Ä¡·á¿ë ¾¾µå ±â±â
- À̽ÄÇü ¾à¹°Àü´Þ ÆßÇÁ ±â±â
Á¦7Àå ½ÃÀå ³»¿ª : ±â¼úº°
- »ýºÐÇØ¼º ÀÓÇöõÆ®
- ºñ»ýºÐÇØ¼º ÀÓÇöõÆ®
Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°
- Á¾¾ç
- ½ÉÇ÷°ü
- ÀÚ°¡¸é¿ªÁúȯ
- »êºÎÀΰú
- ±âŸ
Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦11Àå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ
- °³¿ä
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦13Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦14Àå °¡°Ý ºÐ¼®
Á¦15Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- Abbott Laboratories
- Boston Scientific Corporation
- Delpor Inc.
- Koninklijke DSM N.V.
- Medtronic plc
- Theragenics Corporation
ksm
¿µ¹® ¸ñÂ÷
The global implantable drug delivery devices market size was valued at USD 15.24 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 27.58 Billion by 2033, exhibiting a CAGR of 6.47% during 2025-2033. North America currently dominates the market, holding a significant market share of over 40.7% in 2024. The increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, the growing geriatric population susceptible to chronic disorders, and rapid technological advancements in implantable devices are some of the key factors driving the market.
Implantable drug delivery devices are implanted within the body to enable the sustained release of drugs over an extended period. The construction of these devices involves several key components, including a reservoir or a drug-containing compartment, a release mechanism, and sensors to monitor drug levels or physiological parameters, providing real-time feedback. Implantable drug delivery devices offer numerous advantages over conventional drug administration methods, such as maintaining a constant drug concentration in the bloodstream and avoiding the peaks and troughs associated with oral medications. This ensures optimal therapeutic levels and improves patient compliance. Furthermore, these devices can be programmed to release drugs at specific intervals, reducing the need for frequent dosing and improving convenience for patients. Additionally, implantable drug delivery devices enable localized drug delivery, minimizing systemic side effects and enhancing the efficacy of treatment. Currently, there are various types of implantable drug delivery devices available, including implantable pump, which utilizes a motor-driven mechanism to push the drug out of the reservoir at a controlled rate.
Implantable Drug Delivery Devices Market Trends:
The global implantable drug delivery devices market is primarily accelerated by various factors, including the escalating prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. Moreover, the rising demand for minimally invasive procedures and the growing geriatric population, which is more susceptible to chronic illnesses, are driving the market growth. Additionally, rapid technological advancements in implantable devices, such as the development of biodegradable and programmable drug delivery systems, and the escalating demand for long-term therapeutic solutions are fueling the market growth. Besides this, the escalating need to reduce healthcare costs and the availability of favorable reimbursement policies are bolstering the market growth. In line with this, governments of various nations are undertaking initiatives to promote advanced healthcare technologies, which, in turn, is propelling the market growth. The burgeoning research and development (R&D) activities aimed at introducing novel and innovative implantable drug delivery devices are also driving market expansion. Other factors, such as the growing awareness about the benefits of implantable drug delivery devices and enhancing focus on personalized medicine and targeted drug delivery, are contributing to the market growth.
Key Market Segmentation:
Product Type Insights:
- Implantable Drug Eluting Stents
- Implantable Contraceptive Drug Delivery Devices
- Implantable Intraocular Drug Delivery Devices
- Implantable Brachytherapy Seeds Devices
- Implantable Drug Delivery Pump Devices
Technology Insights:
- Biodegradable Implants
- Non-Biodegradable Implants
Application Insights:
- Oncology
- Cardiovascular
- Autoimmune Diseases
- Obstetrics and Gynecology
- Others
End User Insights:
- Hospitals
- Ambulatory Surgery Centers
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
- The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for implantable drug delivery devices. Some of the factors driving the North America implantable drug delivery devices market included the expanding pharmaceutical industry, the emergence of new drug delivery techniques, the availability of skilled healthcare professionals, and the establishment of specialized clinics and hospitals.
Competitive Landscape:
- The report has also provided a comprehensive analysis of the competitive landscape in the global implantable drug delivery devices market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Boston Scientific Corporation, Delpor Inc., Koninklijke DSM N.V., Medtronic plc, Theragenics Corporation, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
- 1.How big is the implantable drug delivery devices market?
- 2.What is the future outlook of implantable drug delivery devices market?
- 3.What are the key factors driving the implantable drug delivery devices market?
- 4.Which region accounts for the largest implantable drug delivery devices market share?
- 5.Which are the leading companies in the global implantable drug delivery devices market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Implantable Drug Delivery Devices Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Implantable Drug Eluting Stents
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Implantable Contraceptive Drug Delivery Devices
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Implantable Intraocular Drug Delivery Devices
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Implantable Brachytherapy Seeds Devices
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Implantable Drug Delivery Pump Devices
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Biodegradable Implants
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Non-Biodegradable Implants
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Application
- 8.1 Oncology
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cardiovascular
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Autoimmune Diseases
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Obstetrics and Gynecology
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Ambulatory Surgery Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Boston Scientific Corporation
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Delpor Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Koninklijke DSM N.V.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Medtronic plc
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Theragenics Corporation
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
°ü·ÃÀÚ·á